近连续血糖监测使ICU患者血糖控制更安全
这项前瞻性、整群随机、交叉研究在35张床的内外科ICU病区四个独立ICU进行,纳入入院6小时内持续高血糖(血糖>150 mg/dL)和/或接受胰岛素治疗的成人患者,预期住院至少3天。患者置入外周静脉导管并连接连续血糖监测传感器,四个ICU按配对交叉设计随机分为非盲连续血糖监测组(依据监测仪显示血糖调整胰岛素,目标90–150 mg/dL)或盲法间歇血糖监测组(依据间歇血糖读数调整)。共纳入77例(连续监测组39例、间歇监测组38例),记录43,107个血糖值。两组目标范围内时间相似,但连续监测组低血糖发生率(8/39 [20.5%] vs 15/38 [39.5%])和血糖<70 mg/dL时间(0.4% ± 0.9% vs 1.6% ± 3.4%;p < 0.05)均低于间歇监测组。结论认为基于连续血糖监测的策略降低低血糖发生率和严重程度,从而改善血糖控制安全性。
要点
- 连续血糖监测组低血糖发生率8/39(20.5%),低于间歇监测组15/38(39.5%)。
- 连续血糖监测组血糖<70 mg/dL时间0.4% ± 0.9%,低于间歇监测组1.6% ± 3.4%(p < 0.05)。
- 两组目标范围内时间相似,提示低血糖减少未以牺牲血糖控制范围为代价。
- 研究纳入入院6小时内血糖>150 mg/dL和/或接受胰岛素治疗、预期ICU停留至少3天的成人患者。
- 胰岛素输注速率调整目标为血糖90–150 mg/dL,依据连续监测显示值或间歇血糖读数执行。
适用人群与场景
- 成人患者,收入35张床的内外科ICU病区,预期停留至少3天。
- 纳入条件为入院6小时内持续高血糖(血糖>150 mg/dL)和/或正在接受胰岛素治疗。
诊断标准与关键阈值
- 持续高血糖定义为血糖>150 mg/dL且持续至入院后6小时。
- 血糖控制目标范围为90–150 mg/dL。
- 低血糖定义为血糖<70 mg/dL。
处置流程与药物剂量
- 所有患者置入外周静脉导管并连接连续血糖监测传感器(GlucoClear;Edwards Lifesciences,Irvine,CA)。
- 四个ICU按配对交叉设计随机分为非盲连续血糖监测组或盲法间歇血糖监测组。
- 连续血糖监测组依据监测仪显示的血糖值调整胰岛素输注速率,目标血糖90–150 mg/dL。
- 间歇血糖监测组依据间歇血糖读数调整胰岛素输注速率,目标血糖90–150 mg/dL。
研究设计与关键结果
- 研究设计为前瞻性、整群随机、交叉研究,在35张床的内外科ICU病区四个独立ICU进行。
- 共纳入77例患者:连续血糖监测组39例,间歇血糖监测组38例;记录43,107个血糖值。
- 两组目标范围内时间相似。
- 低血糖发生率:连续血糖监测组8/39(20.5%)vs 间歇血糖监测组15/38(39.5%)。
- 血糖<70 mg/dL时间:连续血糖监测组0.4% ± 0.9% vs 间歇血糖监测组1.6% ± 3.4%(p < 0.05)。
证据类型、等级与局限
- 证据类型:前瞻性、整群随机、交叉研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在符合纳入条件的ICU成人高血糖患者中,使用近连续血糖监测指导胰岛素调整可降低低血糖发生率和血糖<70 mg/dL时间。
- 两组目标范围内时间相似,提示连续监测在减少低血糖的同时未明显改变总体血糖控制范围。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Tight glycemic control using intermittent blood glucose measurements is associated with a risk of hypoglycemia. Glucose concentrations can now be measured near continuously (every 5-15 min). We assessed the quality and safety of glycemic control guided by a near-continuous glucose monitoring system in ICU patients.
DESIGN: Prospective, cluster-randomized, crossover study.
SETTING: Thirty-five-bed medico-surgical department of intensive care with four separate ICUs.
PATIENTS: Adult patients admitted to the department and expected to stay for at least 3 days were considered for inclusion if they had persistent hyperglycemia (blood glucose > 150 mg/dL) up to 6 hours after admission and/or were receiving insulin therapy.
INTERVENTIONS: A peripheral venous catheter was inserted in all patients and connected to a continuous glucose monitoring sensor (GlucoClear; Edwards Lifesciences, Irvine, CA). The four ICUs were randomized in pairs in a crossover design to glycemic control using unblinded or blinded continuous glucose monitoring monitors. The insulin infusion rate was adjusted to keep blood glucose between 90 and 150 mg/dL using the blood glucose values displayed on the continuous glucose monitor (continuous glucose monitoring group-unblinded units) or according to intermittent blood glucose readings (intermittent glucose monitoring group-blinded units).
MEASUREMENTS AND MAIN RESULTS: The quality and safety of glycemic control were assessed using the proportion of time in range, the frequency of blood glucose less than 70 mg/dL, and the time spent with blood glucose less than 70 mg/dL (TB70), using blood glucose values measured by the continuous glucose monitoring device. Seventy-seven patients were enrolled: 39 in the continuous glucose monitoring group and 38 in the intermittent glucose monitoring group. A total of 43,107 blood glucose values were recorded. The time in range was similar in the two groups. The incidence of hypoglycemia (8/39 [20.5%] vs 15/38 [39.5%]) and the TB70 (0.4% ± 0.9% vs 1.6% ± 3.4%; p < 0.05) was lower in the continuous glucose monitoring than in the intermittent glucose monitoring group.
CONCLUSIONS: Use of a continuous glucose monitoring-based strategy decreased the incidence and severity of hypoglycemia, thus improving the safety of glycemic control.
参考来源
- Preiser JC, Lheureux O, Thooft A, et al. Near-Continuous Glucose Monitoring Makes Glycemic Control Safer in ICU Patients. Crit Care Med. 2018. PMID: 29677007. doi:10.1097/CCM.0000000000003157
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。